StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/307% below fair value
$165.31−2.09 (-1.25%)

Close on Nov 16, 2026Market cap $16.80BP/E 24.2Yield –

Neurocrine Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Neurocrine Biosciences

Neurocrine Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Neurocrine Biosciences figures

See a number that looks wrong?